​​​
  1. Cipla, BMS settle Hepatitis B drug dispute out of court

Cipla, BMS settle Hepatitis B drug dispute out of court

The patent dispute between US-based pharma major Bristol-Myers Squibb (BMS) and Cipla over Entecavir...

By: | Chennai | Updated: June 18, 2015 12:27 AM

The patent dispute between US-based pharma major Bristol-Myers Squibb (BMS) and Cipla over Entecavir, a combination for treating Hepatitis B, has been settled amicably out of court.

The Intellectual Property Appellate Board (IPAB) on Wednesday, taking into consideration the endorsement by the warring parties, dismissed the original rectification application filed by Cipla against BMS’ patent. The counsels appearing for both the parties informed the IPAB that the matter has been settled out of court in April, 2015. The IPAB bench comprising Justice KN Basha and DPS Parmar, technical member – patent dismissed the application as withdrawn not pressed. The companies requested the terms of settlement has to be kept confidential.

For Updates Check Company News; follow us on Facebook and Twitter

Get live Stock Prices from BSE and NSE and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Tags: Cipla

Go to Top